NEFL and Alzheimer disease: The assays, developed using the ultrasensitive S-PLEX ECL assay format (19–22), performed well and detected higher plasma levels of all four biomarkers in individuals with AD compared to both individuals with normal cognition and, with the exception of NfL, individuals with other non-AD neurodegenerative diseases.